Amanta Healthcare Posts 5% Revenue Growth in Q1 FY27, Eyes Major Expansion

Amanta Healthcare reported Q1 FY27 revenue of ₹69 crore, a 5% increase year-on-year. EBITDA stood at ₹15 crore with a 22% margin.

Reader Takeaway: Capacity expansion underway; monitor execution risks and margin targets.

What just happened

Amanta Healthcare announced its first-quarter results for the fiscal year 2027, showing a 5% year-on-year increase in revenue to ₹69 crore. The company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) was ₹15 crore, maintaining a 22% margin.

Why this matters

The results signal steady growth for Amanta Healthcare. More importantly, the company is undertaking significant capacity expansions, including its SteriPort facility, which is crucial for its future revenue targets and market positioning in high-value therapies.

The backstory

Amanta Healthcare is focused on expanding its manufacturing capabilities to meet growing demand and tap into regulated markets. The company has been investing in new lines and facilities to enhance its product offerings and market reach.

What changes now

With the Q1 FY27 results, Amanta Healthcare has reaffirmed its growth strategy. The focus shifts to the timely commissioning of its expanded SteriPort line and the new Small Volume Parenteral (SVP) facility, expected to drive future revenue and profitability.

Risks to watch

Key risks include potential delays in the commissioning of the SteriPort Line 3, which has already faced a 4-5 month delay. Volatility in input costs, particularly polymers, and the long working capital cycles inherent in sterile product manufacturing are also points to monitor.

Peer comparison

While specific peer results for Q1 FY27 are not detailed here, Amanta Healthcare's focus on expanding capacity for specialized therapies and regulated markets suggests a strategic move to enhance its competitive standing in the pharmaceutical contract manufacturing sector.

Context metrics (time-bound)

• Q1 FY27 Revenue: ₹69 crore (up 5% YoY)
• Q1 FY27 EBITDA: ₹15 crore (22% margin)
• SteriPort Capacity Expansion: From 6.6 crore to 12 crore bottles/year
• Targeted FY28 Peak Revenue: ₹425 crore
• Targeted FY28 Peak EBITDA: ₹116 crore
• Solar Power Plant commissioned: June 2026 (10.8 MW)
• SteriPort Line 3 Commercial Production expected: August 2026 (delayed)
• SVP Facility Operations expected: March 2027

What to track next

Investors will be closely watching the ramp-up of the SteriPort line in Q3 FY27, the actual reduction in interest costs, and the company's ability to achieve its targeted EBITDA margins of 25%-26% as new capacities and markets are integrated.